Combettes Murielle M J
SERVIER, Institut de Recherches SERVIER, Division Maladies Métaboliques, 11 rue des Moulineaux, 92150 SURESNES, France.
Curr Opin Pharmacol. 2006 Dec;6(6):598-605. doi: 10.1016/j.coph.2006.08.003. Epub 2006 Sep 20.
The first antidiabetic treatment (exenatide; Byetta) based on the incretin hormone glucagon-like peptide-1 (GLP-1) was approved in 2005 as an adjunctive therapy in diabetic patients in whom sulfonylurea, metformin or both had failed. Many GLP-1 mimetics or dipeptidyl peptidase IV inhibitors are currently in clinical development for the treatment of type 2 diabetes and show promising results in the improvement of glucose homeostasis. Furthermore, the ability of GLP-1 to enhance pancreatic beta-cell mass could delay progression of the disease. However, only several years of treatment in humans will confirm the long-term efficacy of GLP-1 mimetics and enhancers on glycemic control. To take advantage of the multifaceted actions of GLP-1, a better understanding of the physiological roles of GLP-1 is required.
首个基于肠促胰岛素激素胰高血糖素样肽-1（GLP-1）的抗糖尿病治疗药物（艾塞那肽；百泌达）于2005年获批，作为磺脲类、二甲双胍或两者治疗失败的糖尿病患者的辅助治疗药物。目前，许多GLP-1类似物或二肽基肽酶IV抑制剂正处于治疗2型糖尿病的临床开发阶段，并在改善葡萄糖稳态方面显示出有前景的结果。此外，GLP-1增强胰腺β细胞量的能力可能会延缓疾病进展。然而，只有数年的人体治疗才能证实GLP-1类似物和增强剂对血糖控制的长期疗效。为了利用GLP-1的多方面作用，需要更好地了解GLP-1的生理作用。
